PMID- 32314519
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1523-5378 (Electronic)
IS  - 1083-4389 (Linking)
VI  - 25
IP  - 4
DP  - 2020 Aug
TI  - Non-bismuth and bismuth quadruple therapies based on previous clarithromycin 
      exposure are as effective and safe in an area of high clarithromycin resistance: 
      A real-life study.
PG  - e12694
LID - 10.1111/hel.12694 [doi]
AB  - BACKGROUND: Bismuth quadruple (BQT) and non-bismuth quadruple (N-BQT) therapies 
      are the recommended first-line treatments for Helicobacter (H.) pylori infection. 
      OBJECTIVE: To compare the efficacy of BQT and N-BQT in clinical practice in an 
      area with high clarithromycin resistance, choosing the regimen on the basis of 
      previous exposure to clarithromycin. METHODS: A total of 404 consecutive 
      H pylori-positive, naive patients were enrolled. A total of 203 patients without 
      previous exposure to clarithromycin received N-BQT, 100 patients for 10 days and 
      103 for 14 days, whereas 201 with previous exposure to clarithromycin received 
      10-day BQT. Efficacy and treatment-related adverse events were assessed. RESULTS 
      AND CONCLUSIONS: Eradication rates by intention-to-treat analysis were 88.2% for 
      N-BQT and 91.5% for BQT (P = .26); per-protocol analysis eradication rates were 
      91.2% and 95.8% for N-BQT and BQT, respectively (P = .07). Eradication rates were 
      significantly higher with 14-day than 10-day CT (P < .003). Almost all patients 
      had a good compliance with both N-BQT (95.6%) and BQT (95%). Adverse events 
      occurred in 24.1% and 26.9% (P = .53) of patients in the N-BQT and BQT group, 
      respectively. In conclusion, clarithromycin-containing non-bismuth or bismuth 
      quadruple therapy, based on the knowledge of previous clarithromycin exposure, is 
      effective and safe even in an area of high prevalence of clarithromycin-resistant 
      H pylori strains.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Romano, Marco
AU  - Romano M
AD  - Division of Hepatogastroenterology, Department of Precision Medicine, University 
      of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Gravina, Antonietta Gerarda
AU  - Gravina AG
AD  - Division of Hepatogastroenterology, Department of Precision Medicine, University 
      of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Nardone, Gerardo
AU  - Nardone G
AD  - Division of Gastroenterology, "Federico II" University, Naples, Italy.
FAU - Federico, Alessandro
AU  - Federico A
AD  - Division of Hepatogastroenterology, Department of Precision Medicine, University 
      of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Dallio, Marcello
AU  - Dallio M
AUID- ORCID: 0000-0003-4153-815X
AD  - Division of Hepatogastroenterology, Department of Precision Medicine, University 
      of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Martorano, Marco
AU  - Martorano M
AD  - Gastroenterology and Endoscopy Unit, Immacolata Hospital, Sapri, Italy.
FAU - Mucherino, Caterina
AU  - Mucherino C
AD  - Gastroenterology and Endoscopy Unit, S. Anna-S. Sebastiano Hospital, Caserta, 
      Italy.
FAU - Romiti, Alessandra
AU  - Romiti A
AD  - Department of Medical and Surgical Sciences, University of Bologna, Bologna, 
      Italy.
FAU - Avallone, Luciana
AU  - Avallone L
AD  - Division of Hepatogastroenterology, Department of Precision Medicine, University 
      of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Granata, Lucia
AU  - Granata L
AD  - Division of Hepatogastroenterology, Department of Precision Medicine, University 
      of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Priadko, Katerina
AU  - Priadko K
AD  - Division of Hepatogastroenterology, Department of Precision Medicine, University 
      of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Compare, Debora
AU  - Compare D
AD  - Division of Gastroenterology, "Federico II" University, Naples, Italy.
FAU - Tuccillo, Concetta
AU  - Tuccillo C
AD  - Division of Hepatogastroenterology, Department of Precision Medicine, University 
      of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Romito, Maria Raffaella
AU  - Romito MR
AD  - Division of Gastroenterology, "Federico II" University, Naples, Italy.
FAU - Sgambato, Dolores
AU  - Sgambato D
AD  - Division of Hepatogastroenterology, Department of Precision Medicine, University 
      of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Miranda, Agnese
AU  - Miranda A
AD  - Division of Hepatogastroenterology, Department of Precision Medicine, University 
      of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Romano, Lorenzo
AU  - Romano L
AD  - Surgical Digestive Endoscopy, Department of Clinical Medicine and Surgery, 
      Federico II University, Naples, Italy.
FAU - Loguercio, Carmelina
AU  - Loguercio C
AD  - Division of Hepatogastroenterology, Department of Precision Medicine, University 
      of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Bazzoli, Franco
AU  - Bazzoli F
AD  - Department of Medical and Surgical Sciences, University of Bologna, Bologna, 
      Italy.
FAU - Zagari, Rocco Maurizio
AU  - Zagari RM
AUID- ORCID: 0000-0001-9949-8619
AD  - Department of Medical and Surgical Sciences, University of Bologna, Bologna, 
      Italy.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200420
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (Antacids)
RN  - 0 (Anti-Bacterial Agents)
RN  - H1250JIK0A (Clarithromycin)
RN  - U015TT5I8H (Bismuth)
SB  - IM
MH  - Adult
MH  - Antacids/*therapeutic use
MH  - Anti-Bacterial Agents/pharmacology/*therapeutic use
MH  - Bismuth/*therapeutic use
MH  - Case-Control Studies
MH  - Clarithromycin/pharmacology/*therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Resistance, Bacterial
MH  - Drug Therapy, Combination
MH  - Female
MH  - Helicobacter Infections/*drug therapy/microbiology
MH  - Helicobacter pylori/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - Pylera
OT  - antimicrobial resistance
OT  - non-bismuth quadruple therapy
EDAT- 2020/04/22 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/01/25 00:00 [received]
PHST- 2020/03/14 00:00 [revised]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1111/hel.12694 [doi]
PST - ppublish
SO  - Helicobacter. 2020 Aug;25(4):e12694. doi: 10.1111/hel.12694. Epub 2020 Apr 20.